CoreDX

Develops medical devices for worldwide infectious disease market


(

Private Fundraise

This company may be interested in raising funds from accredited investors. You must Request Access to see more information about this company.

Request Access 9


Core Diagnostics:
Fast Facts

Our founders saw the potential in developing inexpensive home testing devices for the infectious disease market, starting with COVID-19. With very complimentary backgrounds and skills in the space -- covering IT, chemistry and medical device development -- they decided to initially introduce a specimen collection device as a fast and painless alternative to the long-stem cotton swab for more accurate COVID-19 testing. The end result is a test unlike any other.

      

 


Global Problem Caused by a Global Pandemic
We need better and more accurate testing -- not tomorrow, but right now!

Shortcomings are obvious and significant:

Test is not foolproof

May lead to false positives or inconclusive results

Is inherently flawed because the test cannot adequately retrieve enough specimens collection 100% of the time

It is also, by far, the least inviting/most painful way to get tested for COVID-19


One Incredible Solution
What the world has been waiting for

Designed as an easy, single-use nasal wash aspirator, NACD:

Offers an innovative nozzle and shaped vial that gently sprays sterile fluid into a patient’s nasal cavity and collects the nasal wash back into the vial

Allows for the largest sample size to be collected (outside of a hospital)

Knows that larger sample sizes will significantly reduce false negatives

Was built to be a user-friendly application that removes barrier to use from discomfort


Why We’ll Lead

Built by a quality team, our COVID-19 test is current in the FDA emergency use authorization process. We are about to start testing with an outside consultant and expect to complete the process in November.

This is a Category 1 Device; once certification is complete, we will be shipping the product (could do $1,000,000 in revenue – gross margin is over 50%).

And we could be self-funding the rest of our initiatives by the middle of next year.


Traction & Accomplishments


American-Made Diagnostics

The Cap & Cannula, molded using polypropylene 362OWZ (High-Density Polyethylene) at Piranha Color Systems in Santa Clara, CA.

The Bellow bottle is purchased from LF America its molded-in class 8 cleanroom using 80% EVA 1020 VN5 & 20% LDPE Purell PE 1840 H material.

ePack Flexible Packaging in Austin, Texas, produces the foil pouch (a purchased part).


Meet The Team

John Haughey | CEO

  • 35 years of experience in Operations and Sales
  • Managed $2B global sales revenue at Conner Peripherals
  • Held executive positions including SVP, Seagate Technology, APAC; EVP, Conner Peripherals Executive; President and CEO, OR Technologies; SVP of Global Operations’, BluStor PMC Corporation 

Vince McCord | CFO

  • 30+ years of financial management and executive experience
  • He has served as CFO for 13 private, venture-backed startups and one public company
  • Offers a blend of financial and operations management experience across technology business environments 

George Robinson | VP Operations

  • 40+ years of experience to the team in Technical Support Management, Operations, and Facilities
  • Held senior management positions at Shugart Associates
  • Founder and President of Flexstar Corporation Inc., Greystone Technology Inc., OR Technology, Inc. and Private Label Executive Gifts Inc.
  • Holds a patent on a Bay for Receiving Removable Peripheral Devices 

Wilma Mangan MS | CTO

  • 25 years of experience in point of care assay development and has worked extensively in lateral flow assays
  • Mangan has developed assays for multiple commercial POC products and is an inventor and co-inventor in 13 patents
  • She has managed at least five products from conception to FDA 510K approval
  • Her strengths are in product development, US regulatory affairs and international regulations 

Dr. Ali Khan | Senior Medical Advisor

  • Dr. Khan is a retired assistant surgeon general and is the third dean at the University of Nebraska Medical Center College of Public Health
  • Previously, he served at the CDC for 23 years before retiring as the director of the Office of Public Health Preparedness and Response
  • During his time at the CDC, Dr. Khan led and responded to numerous high-profile domestic and international public health emergencies 

Finis Conner | Strategic Advisor

  • More than 30 years of experience in managing and guiding technology companies with a focus on those providing disruptive solutions
  • Former co-founder of two Fortune 500 companies, Seagate Technologies and Conner Peripherals
  • Holds multiple patents with innovative form factors and looks to apply his deep experience in rapid growth scaling, logistics and operations, raising capital, and executive leadership 

Shep Bentley | Regulatory & Clinical Affairs (FDA) Advisor

  • President and Principal consultant for Bentley Biomedical Consulting LLC, where he is responsible for regulatory strategies leading to FDA approvals
  • With over 35 years in the related medical and med-tech field, he has taken multiple companies from startup to exit by acquisition and looks to apply that experience here 

Dr. Chris Landon MD, FAAP, FCCP, CMD | Senior Medical Advisor

  • For the past three decades Dr. Landon has been the Director of Pediatrics at Ventura County Medical Center
  • Background in medical device development and overseeing clinical trials
  • CEO of the Landon Pediatric Foundation

The Business Plan area is locked. You must Request Access to this company to see more information including the Business Plan.


Request Access

N

No updates yet.




%

No backers yet.




Quick Signup TBD

You must have an account to do this!


the startups.com platform

Copyright © 2019 Startups.com. All rights reserved.

Fundable is a software as a service crowdfunding platform. Fundable is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. Fundable does not recommend or otherwise suggest that any investor make an investment in a particular company, or that any company offer securities to a particular investor. Fundable takes no part in the negotiation or execution of transactions for the purchase or sale of securities, and at no time has possession of funds or securities. No securities transactions are executed or negotiated on or through the Fundable platform. Fundable receives no compensation in connection with the purchase or sale of securities.